Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance
Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance
批准号:
10317747
负责人:
John H Adams
金额:
$73.64万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-02-10 至 2026-06-30
关键词:
AfricaAnabolismAnti-malarial drug resistanceAntimalarialsArtemisininsAsiaBloodBlood CirculationCRISPR/Cas technologyCessation of lifeClinicalCombined Modality TherapyComplexCoupledDNA Sequence AlterationDevelopmentDigestionDiseaseDrug TargetingDrug usageFalciparum MalariaFeverFoodGene Expression ProfileGenesGenetic CrossesGenetic ScreeningGenomeGenomic LibraryGenotypeHeat shock proteinsHeat-Shock ResponseHemeHemoglobinHumanLibrariesLinkMalariaMeasuresMediatingMetabolicModelingMutagenesisMutationOntologyOxidative StressParasitesPathway interactionsPharmaceutical PreparationsPharmacotherapyPhenotypePlasmodiumPlasmodium falciparumPlasmodium vivaxProcessProteinsReactive Oxygen SpeciesResearchResistanceToxic effectVacuoleartesunateasexualbiological adaptation to stresscomparativecostdocosahexaenoylascorbic aciddrug discoveryfitnessgene discoverygenome editingglobal healthinhibitor/antagonistisoprenoidmulticatalytic endopeptidase complexmutantresponsetooltranscriptome sequencingwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Malaria is a leading cause of human death and illness, causing over 200 million cases of clinical
malaria and 400,000 deaths each year. Traditional measures to control and cure malaria are
threatened by emergence of artemisinin resistance (ART-R). Research into ART-R has focused
mostly on mechanisms allowing parasite to tolerate the oxidative stress and protein damage
resulting from ART’s mechanism of action. However, recent discoveries indicate that resistance-
associated mutations in the K13 slows cytostome function to diminish the available hemoglobin in
the food vacuole. Our preliminary results revealed that the parasite’s sensitivity and tolerance to
ART significantly overlaps with innate stress response pathways that enable P. falciparum survival
of malaria fever. Our experimental approach is to elucidate drug-gene associations and decipher
mechanisms of action and resistance to ART and other antimalarial drugs, using forward genetic
screens of P. falciparum mutants created by random piggyBac mutagenesis. This approach has
determined that genetic mutations in the major parasite processes critical for P. falciparum malarial
fever survival response significantly correlate with altered sensitivity to ART (DHA, AS), indicating
the parasite hijacked the heat-shock stress response pathways to cope with ART toxicity. We will
use small libraries of piggyBac clones and GO-focused libraries for iterative screens of different
phenotypes to functionally annotate interacting partners, pathways, and regulatory processes
linked to ART mechanism of action and resistance. We will use genome-level screens to identify
factors linked to ART mechanism of action. We will extend our analysis to P. knowlesi to
characterize the conserved high-value antimalarial drug targets by adapting and applying
chemogenomic profiling analysis to this vivax-like malaria parasite.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine
-
批准号:10307530
-
项目类别:
-
资助金额:$97.6万
-
财政年份:2020
-
负责人:John H Adams
-
依托单位:
Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage
-
批准号:10001705
-
项目类别:
-
资助金额:$20.4万
-
财政年份:2020
-
负责人:John H Adams
-
依托单位:
Plasmodium ovale hypnozoite development and relapse: a coordinated in vivo in vitro study
-
批准号:10304203
-
项目类别:
-
资助金额:$17.68万
-
财政年份:2020
-
负责人:John H Adams
-
依托单位:
Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine
-
批准号:10526422
-
项目类别:
-
资助金额:$97.55万
-
财政年份:2020
-
负责人:John H Adams
-
依托单位:
Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage
-
批准号:10170295
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2020
-
负责人:John H Adams
-
依托单位:
Discovering the essential genome of Plasmodium falciparum
-
批准号:10164710
-
项目类别:
-
资助金额:$64.37万
-
财政年份:2018
-
负责人:John H Adams
-
依托单位:
Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance
-
批准号:10449354
-
项目类别:
-
资助金额:$69.48万
-
财政年份:2015
-
负责人:John H Adams
-
依托单位:
Chemogenomic Profiling of Plasmodium falciparum Drug Responses and Resistance
-
批准号:8864956
-
项目类别:
-
资助金额:$71.84万
-
财政年份:2015
-
负责人:John H Adams
-
依托单位:
Chemogenomic Profiling of Plasmodium falciparum Drug Responses and Resistance
-
批准号:9206137
-
项目类别:
-
资助金额:$71.53万
-
财政年份:2015
-
负责人:John H Adams
-
依托单位:
Chemogenomic Profiling of Plasmodium falciparum Drug Responses and Resistance
-
批准号:9012006
-
项目类别:
-
资助金额:$71.53万
-
财政年份:2015
-
负责人:John H Adams
-
依托单位:
Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance
-
批准号:10658853
-
项目类别:
-
资助金额:$67.86万
-
财政年份:2015
-
负责人:John H Adams
-
依托单位:
Genetic screen for P. vivax CQR
-
批准号:8446957
-
项目类别:
-
资助金额:$18.01万
-
财政年份:2012
-
负责人:John H Adams
-
依托单位:
Genetic screen for P. vivax CQR
-
批准号:8238078
-
项目类别:
-
资助金额:$17.67万
-
财政年份:2012
-
负责人:John H Adams
-
依托单位:
A large-scale transposon mutagenesis screen of Plasmodium falciparum
-
批准号:8803761
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2011
-
负责人:John H Adams
-
依托单位:
A large-scale transposon mutagenesis screen of Plasmodium falciparum
-
批准号:8434199
-
项目类别:
-
资助金额:$37.45万
-
财政年份:2011
-
负责人:John H Adams
-
依托单位:
A large-scale transposon mutagenesis screen of Plasmodium falciparum
-
批准号:8131387
-
项目类别:
-
资助金额:$34.89万
-
财政年份:2011
-
负责人:John H Adams
-
依托单位:
A large-scale transposon mutagenesis screen of Plasmodium falciparum
-
批准号:8620605
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2011
-
负责人:John H Adams
-
依托单位:
A large-scale transposon mutagenesis screen of Plasmodium falciparum
-
批准号:8225119
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2011
-
负责人:John H Adams
-
依托单位:
Immunological characterization of the P. vivax DBP
-
批准号:10599943
-
项目类别:
-
资助金额:$57.77万
-
财政年份:2006
-
负责人:John H Adams
-
依托单位:
Immunological characterization of the P. vivax DBP
-
批准号:9920658
-
项目类别:
-
资助金额:$64.11万
-
财政年份:2006
-
负责人:John H Adams
-
依托单位:
海外基金